DOSE- AND TIME- DEPENDENT PHARMACOKINETICS. CAUSES OF DOSE- OR TIME-DEPENDENT KINETICS PROCESS EXAMPLEPARAMETER Saturable gut wall transport riboflavin.

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
HEPATIC CLEARANCE Q x CA Q x CV Q(CA - CV) 1. Mass Balance
PHARMACOKINETIC.
LAB 3 Enzyme Kinetics Studying -galactosidase activity at varying substrate concentrations in the presence and absence of an inhibitor Michaelis-Menten.
The half-life OCT 2010.
DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
1 METABOLITE KINETICS I. SIGNIFICANCE OF DRUG METABOLITES Reproduced from: Houston JB. Drug metabolite kinetics. Pharmac Ther 15: , 1982.
Nonlinear pharmacokinetics
Body clear- 1 Body clearance OCT 2010 PL Toutain.
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
November 2007 Metabolite Kinetics Theoretical Approach PHM324Y Guest Lecturer Dr. Jasmina Novakovic Apotex Inc, R&D.
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Dose Adjustment in Renal and Hepatic Disease
Gokaraju Rangaraju College of Pharmacy
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
University of Jordan-Faculty of Pharmacy
Quantitative Pharmacokinetics
Nonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Prepared By, Jahanvi H. Patel Roll No:09MPH103 Dept: Pharmaceutical Technology & Biopharmaceutics Guided By: Dhaivat C. Parikh.
Pharmacokinetics Introduction
Non-linear Pharmacokinetics Arthur G. Roberts. Linear Pharmacokinetics AUC dose K Cl dose [Drug] plasma time ln[Drug] plasma time Increasing Dose.
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Atelier PK sur articles. 5 thèmes Absorption / biodisponibilité Métabolisme hépatique et effet de premier passage Les modèles in vitro d’étude de l’absorption.
MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Special Populations: Pediatrics Arthur G. Roberts.
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
NON LINEAR PHARMACOKINETICS Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas 2013.
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
INTRODUCTION CLINICAL PHARMACOKINETICS
Nonlinear Pharmacokinetics
Simultaneous evaluation of the activity of five cytochrome P450 enzymes by a cocktail study in healthy volunteers Department of Pharmacy Practice & Sciences.
Clinical Pharmacokinetic Equations and Calculations
Learning objectives To know what data is available from pharmacokinetic studies in man and how to handle it To know how to calculate the basic pharmacokinetic.
Intrinsic Clearance Arthur G. Roberts. Hydrophobic vs. Hydrophilic more bound to plasma proteins more distributed throughout body more metabolized.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Allie punke Pharmacokinetics tutoring Fall 2016
Anticonvulsants: Phenytoin
Physiology for Engineers
Pharmacokinetics.
Excretion of drugs.
Allie punke Pharmacokinetics tutoring Fall 2016
Chapter 6 EXCRETION OF DRUGS
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics.
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Pharmacokinetics.
Anticonvulsants: Valproic acid
Pharmacokinetics.
Kinetics, Modeling Oct 19, 2009 Casarett and Doull,
Kinetics, Modeling Oct 15, 2006 Casarett and Doull,
affected by their interaction with protein
Enzymes II:kinetics Dr. Nabil Bashir.
Clinical Pharmacokinetics
Hawler Medical University
(BIOC 231) Enzyme Kinetics
NONCOMPARTMENTAL ANALYSIS
Biopharmaceutics Chapter-6
Therapeutic Drug Monitoring chapter 1 part 1
Michaelis-Menten Kinetics
BIOAVAILABILITY.
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
Kidney.
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Drug Metabolism.
Presentation transcript:

DOSE- AND TIME- DEPENDENT PHARMACOKINETICS

CAUSES OF DOSE- OR TIME-DEPENDENT KINETICS PROCESS EXAMPLEPARAMETER Saturable gut wall transport riboflavin F Saturable gut wall metabolism salicylamideF Poor solubilitygriseofulvinF Saturable plasma protein bindingdisopyramidef up Active tubular secretionpenicillin GCL R Active tubular reabsorptionascorbic acidCL R Alterations in urine pHsalicylic acidCL R Alterations in urine flowtheophyllineCL R NephrotoxicitygentamicinCL R

CAUSES OF DOSE- OR TIME-DEPENDENT KINETICS PROCESS EXAMPLEPARAMETER Capacity-limited metabolismphenytoinCL H AutoinductioncarbamazepineCL H Co-substrate depletionacetaminophenCL H Product (metabolite) inhibitionphenylbutazone CL H

I. ABSORPTION Effect of dose on riboflavin urinary recovery when given on an empty stomach. Date from: Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci 55: , 1966.

Effect of dose on ascorbic acid absorption. Data from Blanchard J et al. Am J Clin Nutr 66: , 1997

Steady-state Vitamin C plasma concentration as a function of dose in 13 female subjects receiving doses from 30 to 2,500 mg. From: Levine M, et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98: , 2001.

From: Levine M, et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98: , 2001.

Reproduced from: Rowland M, Tozet TN. Clinical Pharmacokinetics – Concepts and Applications, 3 rd edition, 1995, p. 397.

Reproduced from: Rowland M, Tozer TN. Ibid, p. 396.

II. ELIMINATION A. CAPACITY-LIMITED ELIMINATION 1. MATHEMATICAL ANALYSIS These processes can be described via the Michaelis- Menten relationship:

k -1 is a dissociation process, whereas k+2 requires the breaking of bonds; thus, k -1 >>k +2

Remember that [E f ] = [E T ] – [ES]

The rate of formation of the product is given as: By implication, the maximum rate is given as

For most drugs, K m >>C. Hence

Since Vmax and Km are constant for a given drug in a given individual, this ratio will be constant. Elimination will proceed in a first-order fashion.

Drugs for which K m << C: ethanolsalicylatephenytoin Numerous drugs after first-pass

2. Clinical Consequences a. Relationship btwn dose and C p Reproduced from: Tozer TN, Winter ME. Phenytoin, In: Evans WE, Schentag JJ, Jusko WJ, Applied Pharmacokinetics – Principles for Therapeutic Drug Monitoring. 3 rd edition, 1992, p

b. Relationship btwn dose and time to steady-state From: Ibid.

c. Relationship btwn dose and AUC o Plasma AUC of lorcainide in a subject as a function of dose. Data from: Janchen E et al. Clin Pharmacol Ther 26:187, 1979.

c. Relationship btwn dose and AUC o Plasma AUC/Dose of lorcainide in a subject as a function of dose. Data from: Janchen E et al. Clin Pharmacol Ther 26:187, 1979.

d. Relationship btwn dose and bioavailability Bioavailability of nicardipine after oral administration. Data from: Wagner JG et al. Biopharm Drug Dispos 8: , 1987.

e. Relationship btwn Cp and time

3. Determination of Michaelis-Menten Parameters a. Lineweaver-Burke Expression 1/v 1/C 1/K m 1/V max Slope = K m /V max

b. In Vivo Determination K0K0K0K0 K 0 /C ss V max KmKmKmKm

JB is an 18 yo male receiving phenytoin for prophylaxis of post-traumatic head injury seizures. The following steady state concentrations were obtained at the indicated doses: Dose (mg/d) Css (mg/L) From this data, determine this patients K m and V max for phenytoin.

JB is an 18 yo male receiving phenytoin for prophylaxis of post-traumatic head injury seizures. The following steady state concentrations were obtained at the indicated doses: Dose (mg/d) Css (mg/L) Dose Rate/Css (L/d) K 0 (mg/d) K 0 /C ss (L/d) V max = 362 mg/d K m = 9.7 mg/L

What C ss would be expected if a dose of 200 mg/d were given to this patient?

4. Application to Alcohol Avg V max = 10 g/hr K m = 100 mg/L K m = 100 mg/L Detectable pharmacologic effect: 250 mg/L Lethal concentrations >7000 mg/L

Note: EtOH metabolism becomes zero-order. One jigger (45 mL) of 80 proof EtOH contains ~14 g of ethanol – which exceeds the Vmax! Data from: Rowland M, Tozer TN. Ibid, p. 406.

Reproduced from: Ibid, p. 408.

B. Autoinduction

C. Saturable Renal Tubular Reabsorption Steady-state plasma ascorbic acid concentration in healthy adults receiving various regimens twice daily for 3 to 4 weeks. Control subjects had no supplement. Estimated daily dietary intake of ascorbic acid was mg. From: Nutr Rep Intern 30: , 1984.

Reproduced from: Rowland M, Tozer TN. Ibid, p. 404.

III. SATURABLE PROTEIN BINDING Dose vs AUC for naproxen after single (AUCs) and multiple (AUCm) doses. From: Clin Pharmacol Ther 15: , 1974.

In vitro binding of naproxen as a function of Cp.

Relationship between oral clearance and fraction unbound of oxaprozin. From: J Clin Pharmacol 36: , 1996.